Pharmacokinetic, pharmacodynamic and biomarker study of phase I/II study of olaparib in combination with eribulin mesylate for patients with recurrent or metastatic triple-negative-type breast cancer

Pharmacokinetic, pharmacodynamic and biomarker study of phase I/II study of olaparib in combination with eribulin mesylate for patients with recurrent or metastatic triple-negative-type breast cancer - Pharmacokinetic, pharmacodynamic and biomarker study of Eribulin and Olaparib study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000018721

Enrollment

Registered

2015-08-21

Start date

2013-08-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. A patient who gives informed consent to "A phase I/II Study of Olaparib with Eribulin for inoperable or recurrent triple negative breast cancer with a history of anthracyclines and taxanes" 2. A patient who gives written informed consent

Exclusion criteria

Exclusion criteria: Patient considered irrelevant by attending physician for the study

Design outcomes

Primary

Measure	Time frame
Clinical efficacy and safety Pharmacokinetics Pharmacodynamics Biomarkers	—

Countries

Japan

Contacts

Public ContactAkihiko Shimomura

National Cancer Center Hospital Breast and Medical Oncology

ashimomu@ncc.go.jp03-3542-2511

Outcome results